Ropes & Gray advised Sanofi in a collaboration and global license agreement with EVOQ Therapeutics to develop autoimmune disease therapies by activating regulatory T cells using EVOQ’s NanoDisc technology focused on restoring the body’s natural immune tolerance pathways in a deal worth over $500 million. The collaboration was announced on October 16.
Under the agreement, EVOQ and Sanofi will collaborate on research programs. Sanofi will be responsible for development and commercialization worldwide. EVOQ is eligible to receive over $500 million in total upfront, preclinical, development and sales milestones, as well as tiered royalties on product sales.
The Ropes & Gray team included life sciences licensing partner Abby Gregor and IP transactions and technology counsel Georgina Jones Suzuki.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.